Resources & Guides

Semaglutide has three published human trials on drinking. One met its primary endpoint, one missed it outright, one met its laboratory endpoint but not its real-world measures. Neither the Ozempic nor the Wegovy label says anything about drinking alcohol.

A semaglutide constipation guide built on the Wegovy label, covering the mechanism, label-verified incidence, relief strategies, and when constipation becomes an emergency.

A semaglutide nausea management guide built on the Wegovy label's own numbers and escalation language, not generic tips.

Most semaglutide Reddit roundups just repeat what the community believes. This one checks each recurring claim against the FDA label and the peer-reviewed literature, then labels it corroborated, contradicted, or anecdote only.

Split dosing semaglutide twice weekly takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. Every semaglutide product is FDA-approved for once-weekly dosing only, so this is off-label. Here is the pharmacokinetic reasoning, the pen-mechanics problem, and what has never been tested.

A neutral look at Ro's GLP-1 program: the current branded-only medication lineup, the two-part membership and medication cost structure, and the alternatives.

The oral Wegovy tablet carries the same GLP-1 side effect profile as the rest of the class, but the FDA label handles it differently from the injection. The pen gets a full per-symptom adverse reaction table. The tablet does not. This guide covers what the label actually reports for each format, the dose-ladder timing of GI symptoms, discontinuation rates, the boxed warning, and management strategies.

There is now an oral Wegovy pill: a once-daily 25mg semaglutide tablet FDA-approved on December 22, 2025 for weight management, the first oral GLP-1 cleared for weight loss. This guide covers the dose ladder, the empty-stomach rule, the OASIS-4 results, how it compares to the injectable pen, and why it is a separate product from the diabetes-only Ozempic pill.

Everything you need to know about semaglutide (Ozempic/Wegovy): GLP-1 mechanism, FDA-approved dosing protocols, half-life pharmacokinetics, side effects, and our free calculator to track your journey.

"Ozempic teeth" is an informal name for the dry mouth, enamel erosion, and cavity risk some people notice on semaglutide. This guide explains the three mechanisms, what the FDA label actually says, and the practical steps that protect your teeth.

Ozempic face is the colloquial name for the gaunt, hollowed look that some people notice during rapid semaglutide weight loss. This guide covers the mechanism, who notices it most, whether it reverses, and the lifestyle steps that may soften it.

One chart, all the numbers that matter. Zepbound (tirzepatide) and Wegovy (semaglutide) compared row by row using SURMOUNT-5 head-to-head data, dosing ladders, cost, and FDA approvals.

The complete dual-ladder semaglutide unit conversion reference. Master IU table covering the Wegovy weight-loss titration (0.25 to 2.4 mg) and the Ozempic T2D titration (0.25 to 1.0 mg, optional 2.0 mg) at 2.5 mg/mL and 5 mg/mL.

Semaglutide-associated hair shedding is real, and unlike tirzepatide, alopecia is a labeled adverse event in the Wegovy prescribing information. This guide covers mechanism, dose-stratified risk, and the 6-9 month recovery timeline.

A dated regulatory timeline of the compounded semaglutide ban, from the February 2025 shortage resolution through the April 30, 2026 FDA proposal to remove semaglutide from the 503B bulks list, plus a plain-language 503A vs 503B explainer and a patient action guide.

A pharmacokinetics-grounded guide to switching from semaglutide (Ozempic/Wegovy) to tirzepatide (Mounjaro/Zepbound), covering washout timing, dosing on restart, and outcomes.

Learn exactly how to reconstitute semaglutide peptide powder with BAC water. Includes our free calculator to determine the right concentration, step-by-step instructions, and storage guidelines.

SURMOUNT-5 compared tirzepatide and semaglutide head-to-head for the first time. See the weight loss numbers, mechanism differences, dosing schedules, and which drug may fit your situation.

How much weight can you lose on semaglutide? STEP 1 trial data shows 14.9% mean body weight loss at 68 weeks, with 86.4% of participants losing at least 5%. This guide breaks down the clinical evidence, month-by-month timeline, real-world results, and what factors determine your outcome.

Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes and obesity. It's the active ingredient in Ozempic, Rybelsus, and Wegovy. This guide explains what it is, how it works, what the clinical trials show, and who qualifies for treatment.

Retatrutide achieved 24.2% weight loss vs semaglutide's 14.9% in trials. Compare triple-agonist vs single-agonist mechanisms, approval status, clinical data, side effects, and find out which GLP-1 medication is right for you.

Complete guide to tirzepatide weight loss: SURMOUNT trial results showed 20.9% average weight loss at 72 weeks on 15mg dose. How it works, what to expect, timeline, dosing, comparison with Ozempic/Wegovy, and managing side effects.

Compounded semaglutide costs a fraction of Ozempic or Wegovy but carries distinct risks. This guide covers the FDA regulatory landscape after the 2025 shortage resolution, how to source safely from legitimate pharmacies, dosing considerations, reconstitution, storage, and red flags to watch for.

Tirzepatide achieved 20.9% weight loss vs semaglutide's 14.9% in clinical trials. The SURPASS-2 head-to-head trial showed tirzepatide superior on both A1C and weight. Compare mechanisms, side effects, dosing, costs, and which GLP-1 medication fits your situation.

Both Ozempic and Wegovy contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes (max 1.0 mg) while Wegovy targets obesity (2.4 mg recommended maintenance, 7.2 mg maximum). Explore the differences.

Complete semaglutide dosage chart showing Ozempic (1.0 mg max) and Wegovy (2.4 mg maintenance, 7.2 mg max) titration protocols week-by-week. Includes what to expect at each dose level, side effects data, printable download, and a free dosing calculator.

Semaglutide side effects guide: nausea, diarrhea, and GI symptoms from STEP and SUSTAIN trials, plus practical management tips.

Everything you need to know about semaglutide dosing: GLP-1 mechanism, clinical trial efficacy data, starting dose through maintenance, titration schedules, half-life pharmacokinetics, side effects, and how to use a dosing calculator.

While semaglutide is designed for weekly dosing, its 7-day half-life makes it uniquely suited for split dosing exploration. We examine the pharmacokinetics, protocols, and considerations for microdosing Ozempic and Wegovy.